INBX
NASDAQ · Biotechnology
Inhibrx Biosciences Inc
$93.05
-1.15 (-1.22%)
Open$96.70
Previous Close$94.20
Day High$99.33
Day Low$91.18
52W High$155.29
52W Low$13.97
Volume—
Avg Volume334.5K
Market Cap1.37B
P/E Ratio—
EPS$-6.24
SectorBiotechnology
Analyst Ratings
Strong Buy
9 analysts
Price Target
-80.5% upside
Current
$93.05
$93.05
Target
$18.13
$18.13
$12.39
$18.13 avg
$27.56
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 1.24M | 1.48M | 384.43M |
| Net Income | -133,900,562 | -143,396,603 | -115,444,062 |
| Profit Margin | -10,773.5% | -10,234.8% | -30.0% |
| EBITDA | -126,717,958 | -143,243,764 | -155,644,267 |
| Free Cash Flow | — | — | -85,235,104 |
| Rev Growth | -16.0% | -16.0% | -5.8% |
| Debt/Equity | 12.58 | 12.58 | 0.10 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $243.73 | +3.76% | 105.2 | 382.49B |
| AMGN | Amgen Inc | $356.32 | +1.39% | 23.4 | 182.21B |
| GILD | Gilead Sciences Inc | $124.43 | -0.58% | 16.7 | 153.66B |
| VRTX | Vertex Pharmaceuticals Inc | $484.49 | +1.96% | 26.4 | 114.63B |
| REGN | Regeneron Pharmaceuticals | $625.11 | +0.27% | 14.5 | 63.95B |
| ALNY | Alnylam Pharmaceuticals Inc | $291.90 | -0.73% | 64.3 | 37.13B |